DXCM

DXCM

USD

DexCom Inc. Common Stock

$61.180+0.090 (0.147%)

السعر في الوقت الحقيقي

Healthcare
الأجهزة الطبية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$61.090

الأعلى

$62.390

الأدنى

$58.880

الحجم

8.96M

أساسيات الشركة

القيمة السوقية

23.9B

الصناعة

الأجهزة الطبية

البلد

United States

إحصاءات التداول

متوسط الحجم

5.54M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $56.45الحالي $61.180الأعلى $93.25

تقرير تحليل الذكاء الاصطناعي

آخر تحديث: ٤ نوفمبر ٢٠٢٥
تم إنشاؤه بواسطة الذكاء الاصطناعيمصدر البيانات: Yahoo Finance, Bloomberg, SEC

DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?

Market Pulse Check

  • Current Price: $60.43 (as of 2025-11-03 close)
  • Recent Swing: +3.8% rebound after 61% decline since August highs
  • Key Technicals: MACD bearish crossover vs. surging 19x average volume

Price Action Breakdown

  • August-Sept Stability: Traded $75-$82 range
  • Sept 19 Crash: -11% drop on 3x average volume
  • October Freefall: 35% decline accelerated by legal news
  • November Lifeline: +3.8% gain on massive 17.8M shares traded

News Impact Matrix

SentimentCountKey Developments
Negative96 law firm investigations filed
Analyst Mixed128 lowered PTs (range $75-$99)
Positive1New board member appointment

AI Forecast Snapshot

TimeframePredictionNotes
1-day-0.8%Potential pullback after surge
2-day+1.6%Technical rebound potential
3-day+1.9%Resistance near $62 area

Strategic Considerations

For Active Traders:

  • Watch $61.15 breakout level (Nov 3 high)
  • Consider partial profits at $62.90 TP
  • Hard stop below $58.50 support

Long-term Investors:

  • Monitor lawsuit developments closely
  • Debt concerns (94% D/E ratio) require scrutiny
  • Potential accumulation zone if $58 holds

Bottom Line

DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.


This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.

أخبار ذات صلة

PR Newswire

Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...

عرض المزيد
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Analyst Upgrades

UBS Maintains Buy on DexCom, Lowers Price Target to $95

UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.

عرض المزيد
UBS Maintains Buy on DexCom, Lowers Price Target to $95
Analyst Upgrades

Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82

Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.

عرض المزيد
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Analyst Upgrades

Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80

Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.

عرض المزيد
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
PR Newswire

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...

عرض المزيد
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...

Analyst Upgrades

Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93

Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.

تنبؤ الذكاء الاصطناعيBeta

توصية الذكاء الاصطناعي

صعودي

تم التحديث في: ٤ نوفمبر ٢٠٢٥، ٠٩:٠٩ م

هبوطيمحايدصعودي

60.6% الثقة

المخاطر والتداول

مستوى المخاطرة3/5
مخاطرة متوسطة
مناسب لـ
عدوانيمتحفظنمو
دليل التداول

نقطة الدخول

$58.80

جني الأرباح

$62.91

وقف الخسارة

$52.39

العوامل الرئيسية

يظهر مؤشر DMI اتجاهًا هبوطيًا (ADX:15.5، +DI:9.8، -DI:18.9)، مما يشير إلى الحذر
حجم التداول 19.6 ضعف المتوسط (59,957)، مما يشير إلى ضغط شراء قوي للغاية
مؤشر MACD -0.1446 تحت خط الإشارة -0.0199، مما يشير إلى تقاطع هبوطي

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.